Benzinga·2026-02-09 14:46Legal Action - Novo Nordisk has filed a lawsuit against Hims & Hers for infringing U.S. Patent 8,129,343 related to compounded semaglutide products [1] - The lawsuit claims that Hims & Hers misled consumers and healthcare professionals regarding the clinical benefits and safety of their unapproved drugs [2] Product Safety Concerns - Hims & Hers has been accused of unlawfully mass-compounding injectable semaglutide products with inauthentic active pharmaceutical ingredients (API), posing risks to patient health [2] - The market has been flooded with knock-off versions of Wegovy and Ozempic, which may contain dangerous impurities or incorrect dosages, leading to severe health risks [3] Impurity Levels - Testing by Novo Nordisk revealed that compounded injectable semaglutide drugs contained impurities of up to 86%, while oral versions had impurities as high as 75% [4] - Even small amounts of these impurities can adversely affect drug safety and efficacy, potentially causing serious immune responses [4] Market Reaction - Following the news, Novo Nordisk's stock rose by 6.84% to $50.90, while Hims & Hers' stock fell by 26.93% to $16.83 [5]